You are here: Home » RESULTS » RESULTS 2009-2010

results 2009 – 2010

 

 

 

2010

Current Core & Spec Positions

 

Total Buy & Short Recommendations

 

Total Sell & Buy-to-Cover Recommendations

66

PROFITABILITY

80.3 %

(53/66)

Average % Gain / Loss

+11.9 %

Price Target Accuracy

77 %

(30/39)

Average Duration to Price Target (months)

3.72

 

 

Date

% Profitable Closed CORE and SPEC Positions

% Gain

Q4 2010

 

 

12/30/10

80.6% (54/67)

17%

12/21/10

80.3% (53/66)

10%

12/20/10

80% (52/65)

9%

12/17/10

80% (51/64)

10.5%

12/8/10

80% (48/60)

15%

12/8/10

79.7% (47/59)

8%

12/3/10

79.3% (46/58)

18%

11/29/10

79% (45/57)

Loss

11/20/10

80.4% (45/56)

20%

11/20/10

80% (44/55)

< 4%

11/16/10

79.6% (43/54)

300%

11/12/10

79.2% (42/53)

Loss

10/17/10

Seattle Genetics (SGEN)

33%

10/15/10

80.8% (42/52)

< 4%

10/5/10

80.4% (41/51)

41%

10/5/10

80% (40/50)

< 4%

10/5/10

79.6% (39/49)

9%

Q3 2010

 

 

9.30.10

79.2% (38/48)

12%

9.28.10

BioNiche (BNHLF)

28%

9.24.10

Anika (ANIK)

10.7%

9.23.10

Delcath (DCTH)

19%

9.23.10

iShares Biotech (IBB)

8.5%

9.21.10

78.7% (37/47)

5%

9.10.10

78.3% (36/46)

5%

9.9.10

Symantec (SYMC)

10%

9.3.10

KMG Chemicals (KMGB)

7.5%

9.3.10

77.8% (35/45)

7.5%

9.3.10

Innophos (IPHS)

13%

8.31.10

BioScrip (BIOS)

17.7%

8.31.10

77.3% (34/44)

17.7%

8.30.10

77% (33/43)

Loss

8.26.10

Cereplast (CERP)

18%

8.26.10

78.6% (33/42)

18%

8.25.10

Gold (GLD)

< 4%

8.25.10

78% (32/41)

< 4%

8.11.10

Jazz Pharma (JAZZ)

20%

8.11.10

77.5% (31/40)

20%

8.11.10

77% (30/39)

Loss

8.6.10

81% (30/37)

4%

8.5.10

80.5% (29/36)

23%

8.3.10

Cypress Biosciences (CYPB)

[DK’s Results]

200%

8.3.10

80% (28/35)

< 4%

8.2.10

79.4% (27/34)

19%

7.29.10

Response Genetics (RGDX)

100%+

7.29.10

78.8% (26/33)

5%

7.19.10

Cypress Biosciences (CYPB)

78.1% (25/32)

140%

Q2 2010

 

 

6.19.10

77.4% (24/31)

30%

6.18.10

76.7% (23/30)

10%

6.18.10

75.8% (22/29)

< 4%

6.18.10

75% (21/28)

< 4%

6.18.10

74% (20/27)

7%

6.18.10

73.1% (19/26)

9%

6.18.10

72% (18/25)

14%

6.18.10

70.8% (17/24)

11%

6.18.10

69.5% (16/23)

9%

6.18.10

68.1 % (15/22)

< 4%

6.18.10

66.7% (14/21)

6.7%

6.18.10

65% (13/20)

< 4%

6.18.10

63.1% (12/19)

Loss

6.3.10

85.7% (12/14)

37.5%

6.1.10

84.6% (11/13)

11%

6.1.10

83.3% (10/12)

16%

5.14.10

81.8% (9/11)

Loss

5.14.10

90% (9/10)

13%

5.12.10

88.9% (8/9)

31%

5.11.10

87.5% (7/8)

70%

5.5.10

85.7% (6/7)

143%

4.29.10

83.3% (5/6)

12%

4.27.10

80% (4/5)

39%

4.26.10

75% (3/4)

11%

4.26.10

Portfolio Results from 4/26/2010 (PDF)

 

4.14.10

67% (2/3)

10%

4.14.10

50% (1/2)

30%

4.8.10

Portfolio Results from 4/8/2010 (PDF)

 

Q1 2010

 

 

3/30/10

0% (0/1)

Loss

3/12/10

RXI’s Official Launch

 

3/5/10

Portfolio Results from 3/5/2010 (PDF)

 

Q4 2009

 

 

12.15.09

Portfolio Results from 12/15/2009

 

11.16.09

Portfolio Results from 11/16/2009

 

10.12.09

Portfolio Results from 10/12/2009

 

Q3 2009

 

 

9.16.09

Portfolio Results from 9/16/2009

 

9.11.09 (1)

9.11.09 (2)

Portfolio Results from 9/11/2009

 

8.24.09

Portfolio Results from 8/24/2009

 

8.4.09

Portfolio Results from 8/4/2009

 

Q2 2009

 

 

6/1/09

Cell Therapeutics (CTIC)

2,850%